
    
      OBJECTIVES: I. Determine the efficacy of temozolomide in patients with cisplatin refractory
      metastatic germ cell tumors. II. Determine the safety of this treatment in these patients.

      OUTLINE: Patients receive oral temozolomide on days 1-5. Treatment repeats every 28 days for
      a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.

      PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study over 25 months.
    
  